Pembrolizumab in Small Cell Carcinoma of Ovary - Hypercalcemic Type Patient

• Status: Enrolling by invitation
• Trial end date: 2023-12-06
• Target enrollment: 0
• Participant gender: All

Summary

This is a study of pembrolizumab as consolidation therapy for a patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT).

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University Health Network, Toronto
• Treatments: Pembrolizumab

Criteria

Inclusion Criteria:

• Patient with small cell carcinoma of the ovary, hypercalcemic type (SCCOHT)

Exclusion Criteria:

• N/A